An informal SEC inquiry into the way Amgen handled a Danish study of its anemia drug Aranesp has aroused investors' anxiety, spurring a three percent loss in the value of Amgen shares. Further adding to concerns about Amgen, an expert FDA panel is scheduled to review the safety of anemia drugs on May 10.
- take a look at the CNN report [1] on the Amgen worries
ALSO: A possible change in Medicare's reimbursement formula for Epogen could reduce the amount of money that Amgen is making from the anemia therapy. Report [2]
PLUS: Tony Blair opened Amgen's new European Development Centre in Uxbridge, London. Release [3]
Related Articles:
FDA wants more data on new Aranesp doses. Report [4]
New study points to danger of anemia drug. Report [5]
Major challenges loom for Amgen. Report [6]
Links:
[1] http://money.cnn.com/2007/03/01/news/companies/amgen/?postversion=2007030119
[2] http://www.forbes.com/feeds/ap/2007/03/01/ap3476972.html
[3] http://www.medadnews.com/News/index.cfm?articleid=420107
[4] http://www.fiercebiotech.com/story/fda-wants-more-data-on-new-aranesp-doses/2006-10-16
[5] http://www.fiercebiotech.com/story/new-study-points-to-danger-of-anemia-drug/2006-11-16
[6] http://www.fiercebiotech.com/story/major-challenges-loom-for-amgen/2006-10-26